about
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcomaIncreased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinTrabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo.Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.Neuronal hyperexcitability and seizures are associated with changes in glial-neuronal interactions in the hippocampus of a mouse model of epilepsy with mental retardation.Mode of action of trabectedin in myxoid liposarcomas.Role of Macrophage Targeting in the Antitumor Activity of TrabectedinAntiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1Resistance to minor groove bindersThe impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin
P50
Q28482357-899A2F7A-F0A1-4CC5-AB73-7F716EE1DA56Q36432104-FB7743C0-A06A-41E6-809A-B5AED0C181CBQ38917815-2CC95C6B-97A1-4463-ACBE-8BA6158F7E46Q39401320-4180EECD-B5D4-4839-BE3B-962D8A446F88Q39497253-7C5E16C1-2A2B-4899-A537-2B90A0AC5C89Q42838823-DF3085A1-D4BC-423F-8E04-6599D3D438A5Q45346605-867DB602-1351-4F32-9D2C-4CD1DE545739Q56942258-BD16D7C1-9D9B-4DBD-B368-BAD36E72ACB9Q60048095-25D807C6-8AE3-410E-BE78-9EE649F1F2CCQ60322885-61A7D411-53E7-4A84-93C5-BC9F5B554903Q60322887-32451872-1F9C-4F68-B1FF-6D6633FCE0C0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sarah Uboldi
@ast
Sarah Uboldi
@en
Sarah Uboldi
@es
Sarah Uboldi
@nl
Sarah Uboldi
@sl
type
label
Sarah Uboldi
@ast
Sarah Uboldi
@en
Sarah Uboldi
@es
Sarah Uboldi
@nl
Sarah Uboldi
@sl
prefLabel
Sarah Uboldi
@ast
Sarah Uboldi
@en
Sarah Uboldi
@es
Sarah Uboldi
@nl
Sarah Uboldi
@sl
P106
P21
P31
P496
0000-0002-6430-0323